Search

Displaying results 1731 - 1740 of 7540 in total
  1. Drug

    Ferumoxytol

    go.drugbank.com/drugs/DB06215
    ApprovedInvestigational

    high dose by rapid intravenous injection [L2181]. … In January of 2015, the EMA withdrew marketing authorisation for Rienso (ferumoxytol) due to safety concerns.

    Synonyms: Ferumoxytol non-stoichiometric magnetite
  2. Drug

    Pinaverium

    go.drugbank.com/drugs/DB09090
    ApprovedInvestigational

    Although it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada. … It is shown to relieve GI spasm and pain, transit disturbances and other symptoms related to motility disorders [A19697] and may be considered as effective first-lline therapy for patients with irritable

  3. Drug

    Nilutamide

    go.drugbank.com/drugs/DB00665
    ApprovedInvestigational

    Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). … To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.

    Categories: Antiandrogens, non-steroidal
  4. Drug

    Sepiapterin

    go.drugbank.com/drugs/DB16326
    ApprovedInvestigational

    It is a natural precursor of the enzymatic co-factor tetrahydrobiopterin (BH4), which activates PAH and helps reduce blood phenylalanine levels by enhancing the conformational stability of misfolded PAH … [L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria.

  5. Drug

    Lanadelumab

    go.drugbank.com/drugs/DB14597
    ApprovedInvestigational

    [A38676] Lanadelumab was approved for use in patients with hereditary angioedema by the FDA in August 2018,[L4537] followed by Health Canada in October 2018[L49226] and the EMA in November 2018. … [L4537] It has been granted priority review, breakthrough therapy, and orphan drug designations for rare diseases based on the results of clinical trials.

  6. Drug

    Melatonin

    go.drugbank.com/drugs/DB01065
    ApprovedInvestigationalNutraceuticalVet approved

    ) but outside the blood-brain barrier. … In mammals, melatonin is produced by the pineal gland.

    Synonyms: 5-methoxy-N-acetyl tryptamine, 5-methoxy-N-acetyltryptamine
  7. Drug

    Hexobendine

    go.drugbank.com/drugs/DB13265
    Approved

    It has not been approved in the United States or the United Kingdom, but has been used widely in Austria and Germany [T478]. … Hexobendine is a medication used to cause vasodilation, to treat several conditions including angina pectoris.

  8. Drug

    Dextran

    go.drugbank.com/drugs/DB09255
    ApprovedInvestigationalVet approved

    It is administered by intravenous infusion. Dextran 75 is a complex branched glucan with an average molecular weight 75000 Daltons. … The main chain of glucose has short branches at frequent intervals which are probably joined by 1:3 and 1:4 glucoside links. The chains can be composed of about 200,000 glucose units.

  9. Drug

    Tetrabenazine

    go.drugbank.com/drugs/DB04844
    Approved

    A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. … FDA approved on August 15, 2008.

  10. Drug

    Vilanterol

    go.drugbank.com/drugs/DB09082
    ApprovedInvestigational

    [L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020. … [A259961] Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds

    Categories: Agents to Treat Airway Disease